Marsh & McLennan Companies, Inc. (MRSH) is a professional-services firm whose businesses span risk and insurance services (Marsh, Guy Carpenter) and consulting (Mercer, Oliver Wyman). Because no official published consensus meets the minimum-distance rule relative to the current price, the $210 central target is calculated here as the average of only the analyst targets above the current price, using ten verified targets with firm names and dates.
The most recent individual targets include JPMorgan at $218 (Overweight), UBS at $216 (Buy), Keefe Bruyette at $201 (Market Perform), Mizuho at $201 (Neutral), Morgan Stanley at $200 (Equal-Weight), Goldman Sachs at $200 (Buy), Roth MKM at $200 (Hold), and Evercore ISI at $236 (Buy). Wells Fargo ($188) and Piper Sandler ($182) round out the lower end of the range. The overall mean of all ten is roughly $204, close to the widely cited average analyst price target near $205, while the full range runs from about $182 to $236.
Views differ mainly on margin trajectory and valuation. Bullish analysts such as JPMorgan point to "stable" organic growth and modestly accelerating margin expansion as cost-savings programs earn through. Keefe Bruyette links its stance to the company's "Thrive" efficiency program driving margin gains into 2026 and 2027. More cautious analysts, including Wells Fargo and Piper Sandler, keep lower targets on concerns about insurance pricing and an already-elevated multiple. Citigroup downgraded the shares to Neutral in late 2026, reflecting that mixed backdrop.
With a latest verified close of $188.50, reaching the $210 central target implies upside of about 11.4%—a modest move for a company whose stock has traded in a wide range over the past year. The shares have recovered from a 52-week low near $157 to the high $180s, though they remain below the analyst-derived objective.
The path toward the target depends on continued execution. Marsh & McLennan generated roughly $28.5 billion in trailing revenue and reported adjusted EPS (earnings per share) of $3.29 in its first quarter, up 8% year over year and above consensus. The company's forward P/E (price-to-earnings) ratio of about 17 is lower than its trailing multiple near 23, suggesting the market is pricing in earnings growth rather than multiple expansion. Reaching $210 would likely require sustained mid-single-digit organic growth, continued margin improvement, and stable investor confidence in the defensive business model.
Several verified factors could support the stock price target. The company's diversified mix of insurance broking and consulting provides revenue resilience, while its low beta (roughly 0.58) makes it attractive in uncertain markets. Management's cost-efficiency programs, referenced by Keefe Bruyette and JPMorgan, are expected to drive margin expansion over the next two years. Share repurchases, a roughly 2.1% dividend yield, and a strong consulting segment (which grew revenue 11% in the first quarter) add further support. Rising complexity in global risk, from cyber to geopolitical exposure, continues to underpin demand for advisory and broking services.
The principal risks are equally verifiable. Declining commercial property and casualty insurance rates pressure the core brokerage business, a theme analysts have cited when trimming estimates. The stock carries a valuation premium relative to the broader financial-services sector, and a first-quarter $425 million litigation charge illustrates exposure to legal and regulatory costs. Slower projected revenue growth—around 4% to 5% annually—and a "Hold"-heavy consensus recommendation (roughly 2.7 on a five-point scale) suggest limited near-term catalysts. Any guidance cut or weaker margin performance could keep the shares below the $210 objective.
The shares have been rebuilding after falling to a 52-week low near $157 in mid-2026, and the recent recovery toward the high $180s reflects improving, though not decisive, momentum. The $210 central target sits above the stock's recent trading range, meaning a sustained move would require clearing the psychological $200 level and any resistance near recent highs. On the downside, the $157 low represents a durable support zone, while the current price near $188 leaves limited distance to that floor. The stock's low beta suggests moves tend to be gradual rather than abrupt.
Analyst price targets generally reflect a research horizon of about twelve months, though individual horizons vary and should not be treated as guarantees. Investors should monitor quarterly earnings and guidance, given that the company typically reports around mid-October, January, April, and July. Key items include organic revenue growth, the margin trajectory from the "Thrive" program, insurance rate trends, consulting demand, share-repurchase activity, and any further analyst target revisions. Citigroup's recent downgrade and JPMorgan's post-earnings increase show how quickly the consensus can shift.
Traders seeking a more dynamic view can use Tickeron's AI Daily Buy/Sell Signals. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It is designed to help traders discover opportunities, track existing positions, and identify shifting trends more efficiently than manual screening. Explore how AI-driven signals can complement fundamental research like the analyst data above.
The question of whether MRSH can reach $210 ultimately rests on execution rather than a single catalyst. The central target is an average of above-price analyst targets—not an official consensus—and sits about 11.4% above the current price, a modest hurdle. Stable organic growth, margin expansion, and a defensive business model support the case, while slowing insurance pricing, a premium valuation, and a cautious "Hold"-leaning analyst base present real obstacles. The wide $182-to-$236 target range underscores genuine disagreement about valuation. With no guarantee of any outcome, investors should focus on upcoming earnings, margin trends, and rate conditions before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MRSH has been closely correlated with BRO. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if MRSH jumps, then BRO could also see price increases.
| Ticker / NAME | Correlation To MRSH | 1D Price Change % | ||
|---|---|---|---|---|
| MRSH | 100% | -0.37% | ||
| BRO - MRSH | 81% Closely correlated | -0.52% | ||
| AJG - MRSH | 80% Closely correlated | -0.34% | ||
| AON - MRSH | 78% Closely correlated | -0.80% | ||
| WTW - MRSH | 65% Loosely correlated | -0.35% | ||
| RYAN - MRSH | 59% Loosely correlated | -1.47% | ||
More | ||||
| Ticker / NAME | Correlation To MRSH | 1D Price Change % |
|---|---|---|
| MRSH | 100% | -0.37% |
| MRSH (5 stocks) | 84% Closely correlated | +4.52% |
| Insurance Brokers/Services (22 stocks) | 67% Closely correlated | +1.46% |
| Insurance (119 stocks) | 64% Loosely correlated | +0.02% |